Cisplatin +/- rucaparib after preoperative chemotherapy in patients with triple-negative or BRCA mutated breast cancer.

Kalra, Maitri; Tong, Yan; Jones, David R; Walsh, Tom; Danso, Michael A; Ma, Cynthia X; Silverman, Paula; King, Mary-Claire; Badve, Sunil S; Perkins, Susan M; Miller, Kathy D

Kalra, Maitri; Tong, Yan; Jones, David R; Walsh, Tom; Danso, Michael A; Ma, Cynthia X; Silverman, Paula; King, Mary-Claire; Badve, Sunil S; Perkins, Susan M; Miller, Kathy D.

Afiliación

Kalra M; Indiana University Melvin and Bren Simon Cancer Center, Indianapolis, IN, USA.
Tong Y; Department of Biostatistics, Indiana University School of Medicine, Indianapolis, IN, USA.
Jones DR; Indiana University Melvin and Bren Simon Cancer Center, Indianapolis, IN, USA.
Walsh T; University of Washington, Seattle, WA, USA.
Danso MA; Virginia Oncology Associates/US Oncology, Norfolk, VA, USA.
Ma CX; Siteman Cancer Center, Washington University, St. Louis, MO, USA.
Silverman P; University Hospitals Ireland Cancer Center, Case Comprehensive Cancer Center, Cleveland, OH, USA.
King MC; University of Washington, Seattle, WA, USA.
Badve SS; Indiana University Melvin and Bren Simon Cancer Center, Indianapolis, IN, USA.
Perkins SM; Department of Biostatistics, Indiana University School of Medicine, Indianapolis, IN, USA.
Miller KD; Indiana University Melvin and Bren Simon Cancer Center, Indianapolis, IN, USA. kathmill@iu.edu.

NPJ Breast Cancer ; 7(1): 29, 2021 Mar 22.

Article en En | MEDLINE | ID: mdl-33753748

Texto completo

Imprimir

XML

PubMed Links

Buscar en Google

Texto completo: 1 Banco de datos: MEDLINE Tipo de estudio: Prognostic_studies Idioma: En Revista: NPJ Breast Cancer Año: 2021 Tipo del documento: Article País de afiliación: Estados Unidos

Texto completo

Imprimir

XML

PubMed Links

Buscar en Google